These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 20045397)
1. Manganese neurotoxic time course is not influenced by L-deprenyl systemic treatment: influence of L-deprenyl in manganese neurotoxic time course. Fernandes A; de Oliveira EF; de Rezende IC; Ponzoni S Brain Res; 2010 Mar; 1317():277-85. PubMed ID: 20045397 [TBL] [Abstract][Full Text] [Related]
4. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons. Rothblat DS; Schneider JS Brain Res; 1998 Jan; 779(1-2):226-30. PubMed ID: 9473679 [TBL] [Abstract][Full Text] [Related]
5. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B]. Knoll J Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565 [TBL] [Abstract][Full Text] [Related]
6. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151 [TBL] [Abstract][Full Text] [Related]
7. Intrapallidal injection of 6-hydroxydopamine induced changes in dopamine innervation and neuronal activity of globus pallidus. Bouali-Benazzouz R; Tai CH; Chetrit J; Benazzouz A Neuroscience; 2009 Dec; 164(2):588-96. PubMed ID: 19628021 [TBL] [Abstract][Full Text] [Related]
8. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490 [TBL] [Abstract][Full Text] [Related]
9. Attenuation of paraquat-induced dopaminergic toxicity on the substantia nigra by (-)-deprenyl in vivo. Liou HH; Chen RC; Chen TH; Tsai YF; Tsai MC Toxicol Appl Pharmacol; 2001 Apr; 172(1):37-43. PubMed ID: 11264021 [TBL] [Abstract][Full Text] [Related]
10. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Rosenblad C; Kirik D; Björklund A Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072 [TBL] [Abstract][Full Text] [Related]
11. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. Mytilineou C; Leonardi EK; Radcliffe P; Heinonen EH; Han SK; Werner P; Cohen G; Olanow CW J Pharmacol Exp Ther; 1998 Feb; 284(2):700-6. PubMed ID: 9454817 [TBL] [Abstract][Full Text] [Related]
12. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease. Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. Paterson IA; Juorio AV; Berry MD; Zhu MY J Pharmacol Exp Ther; 1991 Sep; 258(3):1019-26. PubMed ID: 1679846 [TBL] [Abstract][Full Text] [Related]
14. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences. Ahmad M; Saleem S; Ahmad AS; Yousuf S; Ansari MA; Khan MB; Ishrat T; Chaturvedi RK; Agrawal AK; Islam F J Neurochem; 2005 Apr; 93(1):94-104. PubMed ID: 15773909 [TBL] [Abstract][Full Text] [Related]
15. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine. Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197 [TBL] [Abstract][Full Text] [Related]
16. Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway. Vrana SL; Azzaro AJ; Vrana KE Mol Pharmacol; 1992 May; 41(5):839-44. PubMed ID: 1350320 [TBL] [Abstract][Full Text] [Related]
17. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. Engberg G; Elebring T; Nissbrandt H J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311 [TBL] [Abstract][Full Text] [Related]
18. Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats. Glavan G; Zivin M Neuroscience; 2005; 135(2):545-54. PubMed ID: 16111820 [TBL] [Abstract][Full Text] [Related]
19. [Medicamentous strategy for improving the quality of life in the senescence]. Knoll J Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965 [TBL] [Abstract][Full Text] [Related]
20. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron. Knoll J J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]